|
Leukemia, Myelocytic, Acute
|
|
0.750 |
GeneticVariation
|
CLINVAR |
Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation.
|
23149070 |
2013 |
|
Leukemia, Myelocytic, Acute
|
|
0.750 |
GeneticVariation
|
BEFREE |
We found the activity of protein phosphatase 2A (PP2A), a human tumor suppressor whose dysfunction contributes to malignant cell behavior, was significantly decreased in AML subgroups harboring C-KIT/D816V and AML cell line Kasumi-1 bearing C-KIT/N822K mutation.
|
22109829 |
2012 |
|
Leukemia, Myelocytic, Acute
|
|
0.750 |
GeneticVariation
|
BEFREE |
Interestingly, coexpression of AE and HyC-KIT N822K led to fatal AML.
|
21262832 |
2011 |
|
Leukemia, Myelocytic, Acute
|
|
0.750 |
GeneticVariation
|
BEFREE |
The t(8;21) Acute Myeloid Leukaemia (AML) Kasumi-1 cell line with N822K KIT mutation, is a model system for leukemogenesis.
|
20227111 |
2010 |
|
Leukemia, Myelocytic, Acute
|
|
0.750 |
GeneticVariation
|
BEFREE |
However, the 5 KIT-mutated cases (D816H, 3; D816Y, 1; and N822K, 1) of t(8; 21) AML had diminished CD19 expression (P = .04) with definite CD56 expression (P = .30) on myeloid blasts.
|
17875504 |
2007 |
|
Leukemia, Myelocytic, Acute
|
|
0.750 |
GeneticVariation
|
BEFREE |
Kasumi-1 is t(8;21) acute myeloid leukemia (AML) cell line harboring mutated KIT with Asn822Lys substitution.
|
16213582 |
2006 |
|
Gastrointestinal Stromal Tumors
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
[Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
|
22932406 |
2012 |
|
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
KIT as a therapeutic target in metastatic melanoma.
|
21642685 |
2011 |
|
Gastrointestinal Stromal Tumors
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
|
17699867 |
2007 |
|
Gastrointestinal Stromal Tumors
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
|
15685537 |
2005 |
|
Testicular Germ Cell Tumor
|
|
0.700 |
GeneticVariation
|
UNIPROT |
|
|
|
|
Core binding factor acute myeloid leukemia
|
|
0.040 |
GeneticVariation
|
BEFREE |
Previous studies have indicated similar proliferation and apoptosis between N822K and D816V mutations.The current study aims to determine the occurrence and potential functions of N822K mutation-induced c-KIT activation in AML cells, and explore possible mechanisms of poor prognosis of CBF-AML.
|
31217744 |
2019 |
|
Core binding factor acute myeloid leukemia
|
|
0.040 |
GeneticVariation
|
BEFREE |
KIT mutations, such as N822K, have been found in 30% of core binding factor-AML (CBF-AML) patients.
|
31484543 |
2019 |
|
Core binding factor acute myeloid leukemia
|
|
0.040 |
GeneticVariation
|
BEFREE |
D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia.
|
28506695 |
2017 |
|
Core binding factor acute myeloid leukemia
|
|
0.040 |
GeneticVariation
|
BEFREE |
In the present study, we analyzed the prognostic significance of each KIT mutation (D816, N822K, and other mutations) in Japanese patients with CBF-AML.
|
28762080 |
2017 |
|
Childhood Leukemia
|
|
0.030 |
GeneticVariation
|
BEFREE |
N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells.
|
31484543 |
2019 |
|
leukemia
|
|
0.030 |
GeneticVariation
|
BEFREE |
N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells.
|
31484543 |
2019 |
|
Childhood Leukemia
|
|
0.030 |
GeneticVariation
|
BEFREE |
Furthermore, dasatinib prolonged lifespan of mice bearing AE and HyC-KIT N822K-coexpressing leukemic cells and exerted synergic effects while combined with cytarabine, thus providing a potential therapeutic for t(8;21) leukemia.
|
21262832 |
2011 |
|
leukemia
|
|
0.030 |
GeneticVariation
|
BEFREE |
Here we studied the effects of Bacillus intermedius RNase (binase) on murine myeloid progenitor cells FDC-P1; transduced FDC-P1 cells ectopically expressing mutated human KIT N822K oncogene and/or human AML1-ETO oncogene; and human leukemia Kasumi-1 cells expressing both of these oncogenes.
|
22101339 |
2011 |
|
leukemia
|
|
0.030 |
GeneticVariation
|
BEFREE |
Furthermore, dasatinib prolonged lifespan of mice bearing AE and HyC-KIT N822K-coexpressing leukemic cells and exerted synergic effects while combined with cytarabine, thus providing a potential therapeutic for t(8;21) leukemia.
|
21262832 |
2011 |
|
Childhood Leukemia
|
|
0.030 |
GeneticVariation
|
BEFREE |
Here we studied the effects of Bacillus intermedius RNase (binase) on murine myeloid progenitor cells FDC-P1; transduced FDC-P1 cells ectopically expressing mutated human KIT N822K oncogene and/or human AML1-ETO oncogene; and human leukemia Kasumi-1 cells expressing both of these oncogenes.
|
22101339 |
2011 |
|
Dysgerminoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Next to these, three codon N822K mutations were detected in the group of 15 pure ovarian dysgerminomas.
|
22937135 |
2012 |
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Molecular analysis showed a somatic 6-base pair deletion in exon 11 of c-KIT (W557_K558del) in both the primary tumor and the third recurrence; the recurrence had an additional exon 17 mutation (N822K).
|
21237497 |
2011 |
|
Myeloproliferative disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
In mice, HyC-KIT N822K induced a myeloproliferative disease, whereas HyC-KIT 571+14 induces both myeloproliferative disease and lymphocytic leukemia.
|
21262832 |
2011 |